With the ever-mounting evidence for a profound and direct effect of SGLT2 inhibitors (SGLT2is) on the heart, understanding their mechanism of action becomes increasingly important. So, we are pleased that our paper 1 published in this edition of Cardiovascular Research has generated a lively debate. 2,3 In our work, we use a variety of methods to show that, at least in our hands, empagliflozin (EMPA) from two independent suppliers, as well as two other chemically related SGLT2is, are not potent inhibitors of the cardiac Na+/H+ exchanger-1 (NHE1) and, related to this, have no effect on intracellular Na+ concentration ([Na+]i) in the healthy heart. This is contrary to several previous reports (see references 1–4 in Zuurbier et al. 2).